Which is the better option: recombinant human PDGF-BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off-loaded by a customized contact cast?

Abstract	This study compares the efficacy of 0.01% rh-PDGF-BB with standard wound care in 20 patients with diabetes mellitus with neuropathic large plantar ulcers off-loaded with modified total contact cast. The incidence, duration and rate of healing were compared. An accelerated rate of healing in rhPDGF group was observed.
Authors	Anil Bhansali, S Venkatesh, Pinaki Dutta, M S Dhillon, Sambit Das, Aditya Agrawal
Journal	Diabetes research and clinical practice (Diabetes Res Clin Pract) Vol. 83 Issue 1 Pg. e13-6 (Jan 2009) ISSN: 1872-8227 [Electronic] Ireland
PMID	19081156 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References	Platelet-Derived Growth Factor Proto-Oncogene Proteins c-sis Recombinant Proteins Becaplermin
Topics	Adult Aged Becaplermin Diabetic Foot (drug therapy, physiopathology, surgery) Female Humans Male Middle Aged Platelet-Derived Growth Factor (therapeutic use) Proto-Oncogene Proteins c-sis Recombinant Proteins (therapeutic use) Treatment Outcome Wound Healing

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!